Trials / Recruiting
RecruitingNCT06375187
A Study of GC203 TIL in Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety and Efficacy of Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL)in Patients With Advanced Malignant Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Shanghai Juncell Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Engineering Tumor Infiltrating Lymphocytes | A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody. |
Timeline
- Start date
- 2024-05-29
- Primary completion
- 2026-11-01
- Completion
- 2027-05-01
- First posted
- 2024-04-19
- Last updated
- 2025-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06375187. Inclusion in this directory is not an endorsement.